FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to keratin variants. Invention provides therapeutic use of keratin, having efficacy in reducing body temperature rise in fever model in SD rats and prolongation of seizure latency in class III epilepsy in mice; expectorant action in method with release of phenol red in mice; antitussive action in a method for stimulating coughing with an aqueous solution of ammonia in mice and a tendency to reduce the number of writhing in mice and potential analgesic action in acetic acid-induced writhing in ICR mice.
EFFECT: invention can be used in medicine to produce a drug having antipyretic, analgesic, antitussive, expectorant, anticonvulsant and antiepileptic action.
10 cl, 3 dwg, 9 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| KERATIN BD-6, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2020 |
|
RU2825993C1 |
| KERATIN BD-13, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2020 |
|
RU2825991C1 |
| KERATIN BD-3, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2020 |
|
RU2815384C1 |
| KERATIN BD-10, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2020 |
|
RU2823655C1 |
| KERATIN BD-1, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2020 |
|
RU2825994C1 |
| KERATIN BD-4, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF | 2020 |
|
RU2824893C1 |
| ANTI-CLAUDIN ANTIBODIES AND USE THEREOF | 2019 |
|
RU2815926C2 |
| ANTI-MESOTHELIN ANTIBODY AND CONJUGATE THEREOF WITH MEDICINAL PRODUCTS | 2019 |
|
RU2747995C1 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| HIGH GLYCATED FUSED PROTEIN BASED ON HUMAN BLOOD COAGULATION FACTOR VIII, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2016 |
|
RU2722374C1 |
